T-cube Platform: Enabling Safer & More Effective Next-Generation T-Cell Engagers
- Outlining how T-cube activates T-cells only in the presence of tumor-associated antigens by leveraging CD137, minimizing off-tumor activation, and reducing the risk of systemic toxicity
- Evaluating how, by avoiding direct CD3 engagement, T-cube significantly lowers the risk of cytokine release syndrome while maintaining strong antitumor activity in solid tumors
- Discussing how the modular T-cube architecture supports multiple bispecific programs -AP203, AP402, and AP601- each targeting distinct tumor biology and high-value indications